Blueprint Medicines Corp 2024 Sustainability Report
Company: Blueprint Medicines Corp
Sector: Manufacturing
Country: United States
Year: 2024
Type: Sustainability Report
Pages: 16
The report describes Blueprint Medicines' 2024 efforts to expand patient access, including approximately $44.5 million of free AYVAKIT and $4.4 million in co-pay assistance. It reports 95% patient satisfaction and broad education and support activities for people living with systemic mastocytosis. For employees, the report highlights 96% survey participation and an average of 64 formal learning and development hours. Environmentally, the company completed its first Scope 1 and 2 GHG inventory, reporting both market-based and location-based Scope 2 emissions.
Reporting standards, commitments and assurance details are available with a free account.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.